Attached files
file | filename |
---|---|
8-K - CURRENT REPORT - Sunshine Biopharma, Inc | sbfm_8k.htm |
Exhibit 99.1
For Immediate Release
June 3, 2020
SUNSHINE BIOPHARMA FILES A PATENT APPLICATION FOR A
NEW
CORONAVIRUS COVID-19 TREATMENT
Montreal,
Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC
Pink Sheets: “SBFM”), a pharmaceutical company focused
on the research, development and commercialization of drugs for the
treatment of aggressive forms of cancer today announced that it has
filed a patent application in the United States for a new treatment
for Coronavirus infections, including COVID-19. Sunshine’s
patent application covers composition subject matter pertaining to
small molecules for inhibition of the main Coronavirus protease
(Mpro), an enzyme that is essential for viral replication. The
small molecules covered by the patent application were computer
modelled and designed by Dr. Steve N. Slilaty, CEO of Sunshine
Biopharma. The patent application has a priority date of May 22,
2020.
“The
causative agent of the current COVID-19 global pandemic is Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), one of
several strains of Coronavirus capable of infecting humans and
causing serious illness. SARS-CoV-2 produces several functional
proteins in infected human cells by cleaving them from two
overlapping viral ‘polyproteins,’ pp1a and pp1ab. One
of these functional proteins is a cysteine protease referred to as
the main protease (Mpro, also called 3CLpro and nsp5). Mpro cleaves
the viral ‘polyproteins’ at a number of specific sites
thereby generating a multi-subunit protein complex termed
‘viral replicase-transcriptase’. Because of its
functional indispensability in viral replication, Mpro is an
attractive drug target for the development of a treatment for
COVID-19 and other Coronavirus infections,” said Dr.
Slilaty.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not
strictly historical, including statements as to revenue
projections, business strategy, outlook, objectives, future
milestones, plans, intentions, goals, future financial conditions,
future collaboration agreements, the success of the Company's
development, events conditioned on stockholder or other approval,
or otherwise as to future events, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The forward-looking statements contained in this release are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements made.
For Additional Information:
Sunshine Biopharma, Inc.
Camille
Sebaaly, CFO
Direct
Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com